EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antibody responses after sequential vaccination with PCV13 and PPSV23 in patients with moderate to severe plaque psoriasis under immunosuppressive therapy

Lorena Helmer, Lukas van de Sand iD, Thea Wojtakowski, Mona Otte, Oliver Witzke, Wiebke Sondermann, Adalbert Krawczyk iD, Monika Lindemann iD

mBio · 2024

DOI: 10.1128/mbio.00482-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Lorena Helmer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, Essen, Germany. Hauptthemen laut MEDLINE: Psoriasis, Pneumococcal Vaccines, Antibodies, Bacterial, Vaccination. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rudolf Ackermann Stiftung (Rudolf-Ackermann-Stiftung).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A crucial step in lowering the risk of invasive pneumococcal illness in high-risk populations, such as individuals with plaque psoriasis, is pneumococcal vaccination. The serologic response to the sequential vaccination with Prevenar 13 (PCV13) and Pneumovax 23 (PPSV23) in psoriasis patients under immunosuppressive therapy is still poorly characterized despite national recommendations suggesting vaccination for immunocompromised patients. In this prospective study, we investigated the serological response in 57 patients under active systemic treatment for moderate to severe plaque psoriasis who underwent sequential vaccination with PCV13 followed by PPSV23. Our analysis focused on global and serotype-specific anti-pneumococcal antibody responses over a 7-month period post-vaccination. Our findings reveal a robust serological response in patients with plaque psoriasis under systemic therapy. When comparing our results with a cohort of kidney transplant recipients who completed a similar sequential vaccination protocol, psoriasis patients showed higher antibody concentrations. In psoriasis patients, the mean levels of all global antibody classes tested (IgG, IgG2, IgA, IgM) increased more than 4-fold ( P < 0.0001) and serotype-specific antibodies more than 1.9-fold ( P < 0.01). In addition to providing strong evidence of the safety and effectiveness of sequential pneumococcal vaccination in individuals with plaque psoriasis, our work sheds light on the complex interactions that exist between immunosuppressive treatment, vaccination schedule, and antibody responses in various risk groups. IMPORTANCE To protect against severe courses of infection with Streptococcus pneumoniae , the national guidelines recommend sequential vaccination for these patients. However, there are only studies on the efficacy of a single administration of these vaccines in this particular risk group. The immunological responses to the vaccine were correlated with clinical patient data. In summary, our study shows for the first time that sequential vaccination is immunogenic in patients with moderate to severe plaque psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisPneumococcal VaccinesAntibodies, BacterialVaccinationHumansMaleFemaleMiddle AgedProspective StudiesAdultPneumococcal InfectionsAntibody FormationAgedStreptococcus pneumoniaeImmunosuppressive AgentsImmunocompromised HostYoung AdultImmunosuppression Therapy

Stichwörter der Autor:innen

Streptococcus pneumoniaepneumococcal antigenspsoriasissequential vaccinationserotype-specific immunityvaccination

Substanzen

Pneumococcal VaccinesAntibodies, Bacterial23-valent pneumococcal capsular polysaccharide vaccine13-valent pneumococcal vaccineImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Department of Dermatology, Venereology and Allergology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Institute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

ORCID-Profile: Lukas van de Sand, Adalbert Krawczyk, Monika Lindemann

Förderung

  • Rudolf Ackermann Stiftung (Rudolf-Ackermann-Stiftung)

Zitieren

APA

Helmer, L., van de Sand, L., Wojtakowski, T., Otte, M., Witzke, O., Sondermann, W., Krawczyk, A., & Lindemann, M. (2024). Antibody responses after sequential vaccination with PCV13 and PPSV23 in patients with moderate to severe plaque psoriasis under immunosuppressive therapy. mBio. https://doi.org/10.1128/mbio.00482-24

Vancouver

Helmer L, van de Sand L, Wojtakowski T, Otte M, Witzke O, Sondermann W, et al. Antibody responses after sequential vaccination with PCV13 and PPSV23 in patients with moderate to severe plaque psoriasis under immunosuppressive therapy. mBio. 2024. doi:10.1128/mbio.00482-24

BibTeX
@article{Helmer2024,
  author = {Helmer, Lorena and van de Sand, Lukas and Wojtakowski, Thea and Otte, Mona and Witzke, Oliver and Sondermann, Wiebke and Krawczyk, Adalbert and Lindemann, Monika},
  title = {Antibody responses after sequential vaccination with PCV13 and PPSV23 in patients with moderate to severe plaque psoriasis under immunosuppressive therapy},
  journal = {mBio},
  year = {2024},
  doi = {10.1128/mbio.00482-24}
}
Kostenlos starten →